
More than 3.5 million people in the UK live with a rare condition

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities

Desmoid tumours are rare soft tissue tumours that can grow aggressively into nearby tissues

The company will pay $435m in up front and near-term milestone payments

The real-world findings support the long-term benefits of continuous treatment

The acquisition will expand the company’s immunology pipeline

In the study, there were improvements in motor function as well as a slowing of neurodegeneration

The acquisition will advance innovation for patients with rare skin diseases

The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases

SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK

The rare disease affects around one in every 22,000 people worldwide